Updates on Combination Therapy for Advanced Prostate Cancer
13 Aug 2025
10:40
11:00
David PensonUnited States
Speaker
Comparison of Various Treatment Options for Localized Prostate CancerThere are numerous therapeutic strategies used to treat localized prostate cancer, each with unique advantages and disadvantages. Furthermore, prostate cancer itself is heterogeneous with some tumors being indolent and others being more aggressive. We will from the presentation by looking at outcomes separately in patients with favorable prognosis and those with unfavorable prognosis, based upon baseline clinical characteristics. We will first compare cancer control and mortality outcomes amongst the various options. We will then present data on patient-reported outcomes. At the conclusion of the presentation, attendees will have a better understanding of outcomes following treatment for localized prostate cancer and will be better prepared to counsel patients newly diagnosed with this common malignancy.Updates on Combination Therapy for Advanced Prostate CancerOver the past decade, there are have been significant advances in the treatment of metastatic prostate cancer. Randomized clinical trial data have demonstrated that combination therapies are superior to monotherapy in terms of cancer control and survival. Various treatment options will be discussed for metastatic castrate-sensitive and -resistant prostate cancer. These will be compared in terms of efficacy and side effect profiles to aid in treatment selection in this The Startup of An Academic Urologist - How to Build up Your Team in Clinical ResearchMany young academic urologists wish to perform clinical research at their institution. Often, however, this is challenging due to lack of resources or time. In this presentation, we will discuss how to build a clinical research program, including identifying what types of individuals need to be part of the team and what sort of resources are required for success. While American examples will often be used, information from this presentation will still be applicable globally.A Programmatic Approach to Prostate Cancer ScreeningProstate cancer screening has advanced beyond annual PSA testing. We now have numerous tools available to aid in identifying men at risk for harboring clinically significant prostate cancer, including MRI and various novel biomarkers. In this presentation, we will review these modalities and lay out a systematic approach to screening in 2025.
Over the past decade, there are have been significant advances in the treatment of metastatic prostate cancer. Randomized clinical trial data have demonstrated that combination therapies are superior to monotherapy in terms of cancer control and survival. Various treatment options will be discussed for metastatic castrate-sensitive and -resistant prostate cancer. These will be compared in terms of efficacy and side effect profiles to aid in treatment selection in this